Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to find out if an investigational drug called Dendritic Cell
(DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help
people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute